Caso Clinico 1

Alice Morigi
IRCCS- Azienda Ospedaliera Universitaria
Sant'Orsola.
Istituto di ematologia «L. e A. Seràgnoli», Bologna

REVOLUTIONARY ROAD IN CLL

Innovazione rivoluzionaria nella terapia della leucemia linfatica cronica

Bologna, 20 maggio 2024
Royal Hotel Carlton

Disclosures of Alice Morigi

Company name	Research support	Employee	Consultant	Stockholder	Speakers bureau	Advisory board	Other
Abbvie							
Gilead							
Takeda							
Janssen							
BMS-Celgene							
BeiGene							
Incyte							
Novartis							
Lilly							
Roche							

PATIENT MEDICAL HISTORY

Female, 70 years old

Comorbidities:

- Papillary thyroid cancer treated with thyroidectomy in 2020 with post-surgical hypothyroidism
- Surgery for spinal stenosis in october 2022
- Occult HBV infection

CLINICAL HISTORY

Diagnosis: March 2022 nodal biopsy → B cell lymphocytic leukemia
July 2023 thrombocytopenia (PLTs 6.000/mmc) → Prednisone 1 mg/Kg with initial benefit and recourrence at the sospension

Staging:

- ✓CT scan: showed localization at nodal site max 4.5 cm
- ✓Bone marrow biopsy: positive for B-CLL with BM infiltration of 80%
- ✓Blood tests: WBC: 40.370/mmc (Ly: 80%, Ne: 15%), Hb 12.8 gr/dL, Plts 104.000/mmc, ClCrea 60 ml/min
- ✓ECOG: 0
- ✓CIRS: 8
- ✓Risk factors: del17p absent, TP53 wt, IgVH mutated

B-CLL

STAGE: 4 RAI, BINET C

CLL IPI: 4 high risk

WHICH THERAPY WOULD YOU HAVE CHOSEN?

1) FCR
2) Bendamustine containing regimen
3) Ven-Obi
4) Ibrutinib
5) Acalabrutinib

WHICH THERAPY WOULD YOU HAVE CHOSEN?

1) FCR
2) Bendamustine containing regimen
3) Ven-Obi
4) Ibrutinib
5) Acalabrutinib

OBINUTUZUMAB-VENETOCLAX

VENCLYXTO. Riassunto delle Caratteristiche del Prodotto. Ultima data di revisione del testo 15/09/2023

OBINUTUZUMAB-VENETOCLAX



Medium tumor burden:

- Pre OBI: IV hydratation 2 days before C1D1

- Pre Ven ramp-up
  - IV hydratation same day and the day after a dose escalation
  - Blood exam predose, at 8 and 24 hours after
  - Allopurinol

VENCLYXTO. Riassunto delle Caratteristiche del Prodotto. Ultima data di revisione del testo 15/09/2023

OBINUTUZUMAB-VENETOCLAX

Cycle 1

Day 1-2	Day 8	Day 15	Day 22
Obi 1000 mg	Obi 1000 mg	Obi 1000 mg	**Ven 20 mg**
Plts 104.000/mmc	Plts 116.000/mmc	Plts 130.000/mmc	Plts **41.000/mmc**

grade 3 thrombocytopenia

OBINUTUZUMAB-VENETOCLAX

Cycle 1

Day 1-2	Day 8	Day 15	Day 22
Obi 1000 mg	Obi 1000 mg	Obi 1000 mg	**Ven 20 mg**
Plts 104.000/mmc	Plts 116.000/mmc	Plts 130.000/mmc	Plts **41.000/mmc**

grade 3 thrombocytopenia

Toxicity or recourrence of immune thrombocytopenia?

OBINUTUZUMAB-VENETOCLAX

Cycle 1

Day 1-2	Day 8	Day 15	Day 22	Day 22
Obi 1000 mg	Obi 1000 mg	Obi 1000 mg	**Ven 20 mg**	Ven 20 mg
Plts 104.000/mmc	Plts 116.000/mmc	Plts 130.000/mmc	Plts **41.000/mmc**	**Plts 168.000/mmc**

1 week delay

OBINUTUZUMAB-VENETOCLAX

Cycle 2

Day 1

Obi+Ven
50mg

Plts
181.000/mmc

Day 8

Ven **100mg**

Plts
98.000/mmc

Day 15

Ven **200mg**

Plts
116.000/mmc

Day 22

Ven **400mg**

Plts
90.000/mmc

Cycle 3

Day 1

Obi + Ven
400 mg

Plts 90.000/mmc

Disease evaluation post 3° cycle TB CT → PR (lymph node max 25 mm)

OBINUTUZUMAB-VENETOCLAX



OBINUTUZUMAB-VENETOCLAX



CONCLUSION AND DISCUSSION

- Ongoing cycle 6
- AEs: thrombocytopenia: disease or toxicity?
- Next CT scan at the end of May

CONCLUSION AND DISCUSSION

- Ongoing cycle 6
- AEs: thrombocytopenia: disease or toxicity?
- Next CT scan at the end of May

Thanks for your attention